From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer
Author:
Affiliation:
1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.19.01207
Reference22 articles.
1. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
5. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations;BMC Pulmonary Medicine;2023-11-29
2. Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma;Thoracic Cancer;2023-07-17
3. Prognostic Value and Immunological Role of P4HA3 in Colon Adenocarcinoma;International Journal of General Medicine;2023-05
4. Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards;Interdisciplinary Cancer Research;2023
5. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types;Frontiers in Immunology;2022-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3